Agate Medical Investments

BrainsGate, Ltd., a medical device company, develops therapies for patients suffering from central nervous system (CNS) diseases. It offers a technology platform that involves electrical stimulation of the spheno-palatine ganglion (SPG), a nervous center known to increase cerebral blood flow. The company develops an ischemic stroke system that is based on an implantable electrode and is designed to deliver electrical stimulation to the spheno-palatine ganglion (SPG). Its system augments cerebral blood flow by using an external system temporarily attached to the patient’s cheek. BrainsGate, Ltd. was founded in 2000 and is based in Caesarea, Israel.

CLEW Medical Ltd. develops and delivers an analytics platform for healthcare providers and administrators to predict life threatening complications. Its platform harnesses the available ICU data to deliver predictive clinical analytics that provide hospital management and medical personnel with the preemptive information they require to manage the ICU floor, as well as alerts ICU teams about a patient's deterioration enabling early intervention and improving clinical outcomes. The company was founded in 2014 and is based in Netanya, Israel.

their mission is to develop safe and effective neurovascular medical devices that are beneficial to patients and meet physicians' needs. They are committed to advancing patient care by providing the most reliable, easiest to use and highest quality products supported by proven clinical data. Rapid Medical is located at the northern part of Israel between the Carmel Mountain and the hills of Ramot Menashe.

CLEW Medical Ltd. develops and delivers an analytics platform for healthcare providers and administrators to predict life threatening complications. Its platform harnesses the available ICU data to deliver predictive clinical analytics that provide hospital management and medical personnel with the preemptive information they require to manage the ICU floor, as well as alerts ICU teams about a patient's deterioration enabling early intervention and improving clinical outcomes. The company was founded in 2014 and is based in Netanya, Israel.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

DiA Imaging Analysis Ltd. specializes in developing AI-powered ultrasound analysis technology to enhance cardiac function diagnosis through echocardiographic examinations. The company offers a range of automated solutions, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain, which assesses myocardial strain as an early indicator of reduced left ventricular function. Additional products include LVivo SWM for segmental wall motion analysis, LVivo SAX for coronary heart disease detection, and LVivo Mobile for mobile ultrasound analysis. Founded in 2009 and headquartered in Beersheba, Israel, DiA addresses significant challenges in ultrasound imaging by providing tools that facilitate the acquisition of optimal images and their subsequent analysis. The company’s technology is designed to integrate seamlessly into existing ultrasound devices and healthcare IT systems, making advanced diagnostics more accessible. With FDA and CE clearances for its cardiac toolbox, DiA serves a global user base and generates revenue through its innovative solutions.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Ornim, Inc. is a medical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, the company specializes in non-invasive patient monitoring devices focused on measuring blood flow and oxygen saturation in tissues. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology, which combines light and ultrasound to provide real-time, continuous measurements of cerebral blood flow and regional oxygen saturation. CerOx is notable for being the only device on the market that can simultaneously measure both parameters, while c-FLOW focuses solely on cerebral blood flow. These advanced monitoring solutions are designed to assist healthcare professionals in making informed decisions for neurological treatments and cardiac surgeries, ultimately improving patient care and reducing costs. Ornim holds multiple patents for its innovative technologies, which address the limitations of existing monitoring methods.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

BrainsGate, Ltd., a medical device company, develops therapies for patients suffering from central nervous system (CNS) diseases. It offers a technology platform that involves electrical stimulation of the spheno-palatine ganglion (SPG), a nervous center known to increase cerebral blood flow. The company develops an ischemic stroke system that is based on an implantable electrode and is designed to deliver electrical stimulation to the spheno-palatine ganglion (SPG). Its system augments cerebral blood flow by using an external system temporarily attached to the patient’s cheek. BrainsGate, Ltd. was founded in 2000 and is based in Caesarea, Israel.